EISAI CO LTD (EII DU) stock market data APIs
€25.5469
0.14(0.5%)
as of March 12, 2026
Try our APIs with
free plan!
EISAI CO LTD Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for EII.DU.
Prev. Close
25.5469
Open
25.6869
High
25.8715
Low
25.3963
52 wk Range
20.876-29.612
Market Cap
15 022 M
EPS
46.4
Dividends (Yield)
1.2903
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get EISAI CO LTD data using free add-ons & libraries
Get EISAI CO LTD Fundamental Data
EISAI CO LTD Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-05-14
- EPS/Forecast: 35.18
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
EISAI CO LTD News
New
Evaluating Eisai (TSE:4523) After Mixed Returns And A Modest Undervaluation Signal
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Eisai overview and recent performance snapshot Eisai (TSE:...
Cognito Therapeutics Appoints Thomas Fagan as Executive Vice President, Alzheimer’s Portfolio
Thomas Fagan, Executive Vice President, Alzheimer’s Portfolio, Cognito Therapeutics Former Eisai and Eli Lilly Alzheimer’s disease leader joins executive team to advance commercialization strateg...
Latest data on long-term, real-world treatment with lecanemab will be presented at the AD/PD™ 2026 congress
STOCKHOLM, March 11, 2026 /PRNewswire/ -- BioArctic's AB (publ) (STOCKHOLM: BIOA B) partner Eisai announced today that they will present the latest findings on lecanemab at the 2026 International Conf...
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD™ 2026 Annual Meeting
TOKYO, March 10, 2026 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the company will present the latest findings on lecanemab (generic name, U.S. bra...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
